Healthcare · NSE/BSE: GLAND
Gland Pharma Limited Earnings Summary — Q4 FY2026
Sentiment: Positive
AI-generated summary
Gland Pharma Hits Record Quarterly Net Profit as Margins Rebound to 29%
Key Takeaways
- Q4 FY2026 revenue grew by 22% YoY to 1,743 Cr, marking a steady recovery in sales momentum.
- Operating Profit Margin (OPM) saw a substantial recovery to 29%, reverting toward historical high-performance levels.
- Net Profit nearly doubled year-on-year, surging from 187 Cr in Mar 2025 to 367 Cr in Mar 2026.
- The company maintains a very strong balance sheet with minimal debt and total assets growing to 12,511 Cr.
- Operating cash flow efficiency remains high with CFO/OP at 91% for the full year 2026.
- Other income spiked to 111 Cr in the latest quarter, significantly contributing to the PBT of 506 Cr.
Management Guidance
Management is focused on expanding into complex molecules and CDMO services to sustain long-term growth and counteract generic pricing pressure.
Sentiment Shift
Improving
Outlook
The transition toward complex injectables and the successful navigation of FDA inspections position the company for a recovery in ROE and continued market share gains in the US injectable space.
← Back to Gland Pharma Limited AI analysis
Unlock the full report
Deep-dive sections, financial charts, AI chat and PDF export are available with Premium.
This summary is AI-generated from Gland Pharma Limited's latest annual report and public disclosures. It is for informational purposes only and is not investment advice.